Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2017

View Archived Issues

Vanda acquires license from UCSF for CFTR activators and inhibitors

iDD biotech signs license agreement for antibodies targeting CK8

Icagen collaborates with Bayer to develop new X-ray fluorescence assays

FDA advisory committee recommends approval of subcutaneous rituximab

Spiral signs option agreement with Bionure for SGK agonists for inner ear disorders

Omeros reports further data from phase II trial of OMS-721 in serious kidney disorders

Panacea Biotec launches EasySix in India

Astellas initiates phase IIa study of ASP-0819 for fibromyalgia

Cellectar initiates phase II trial of CLR-131 in relapsed or refractory B-cell malignancies

Merck presents novel GPR40 agoPAMs with potential to enhance gylcemic control

Ninlaro approved in Japan for relapsed or refractory multiple myeloma

CelePlum-777: nanoparticle-based combination of celecoxib and plumbagin for melanoma

Aura's AU-011 begins phase Ib study for ocular melanoma, obtains U.S. fast track designation

The experimental antimalarial DSM-265 shows promise in phase I trials

Corbus reports phase II topline data for anabasum in cystic fibrosis

FDA grants fast track designation to Coversin for PNH

Intuniv approved in Japan for ADHD

Pharmascience discloses new tyrosine-protein kinase BTK inhibitors

Icahn School of Medicine at Mount Sinai presents PP2A-alpha activators

Monash University identifies novel drug conjugates

Progenics' registrational trial of Azedra achieves primary endpoint

Dana-Farber Cancer Institute presents BRD4 and BRDT inhibitors

New Japanese approvals for Stelara and Simponi

Alzheon presents new data informing planned pivotal study of ALZ-801 for mild Alzheimer's disease

Assembly Biosciences and partner disclose hepatitis B core protein modulators

Novo Nordisk resubmits fast-acting insulin aspart NDA

Third Rock Ventures launches Tango Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...